Type 1 and Type 2 5α-Reductase Expression in the Development and Progression of Prostate Cancer

European Urology

Volumn 53, Issue 2, 2008, Pages 244-252

  Thomas, Lynn N ^a   Douglas, Robert C ^a   Lazier, Catherine B ^a   Too, Catherine K L ^a   Rittmaster, Roger S ^b,c   Tindall, Donald J ^d  

^a DALHOUSIE UNIVERSITY   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

^c GLAXOSMITHKLINE   (United States)

^d Mayo Clinic   (United States)

Author keywords

5 Reductase; Benign prostatic hyperplasia; Dutasteride; Enlarged prostate; Finasteride; Prostate cancer

Indexed keywords

ANDROSTANOLONE; DUTASTERIDE; FINASTERIDE; ISOENZYME; PLACEBO; STEROID 5ALPHA REDUCTASE 1; STEROID 5ALPHA REDUCTASE 2; STEROID 5ALPHA REDUCTASE INHIBITOR; TESTOSTERONE;

CANCER GRADING; CANCER GROWTH; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COMPARATIVE STUDY; ENZYME INHIBITION; GENE EXPRESSION; HORMONE SYNTHESIS; HUMAN; IMMUNOHISTOCHEMISTRY; MEDLINE; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE TUMOR; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW;

AZASTEROIDS; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; ENZYME INHIBITORS; FINASTERIDE; HUMANS; ISOENZYMES; MALE; PROSTATIC NEOPLASMS; TESTOSTERONE 5-ALPHA-REDUCTASE;

EID: 37349107226     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2007.10.052     Document Type: Review

References (59)

1. Bonkhoff H., Stein U., Aumuller G., and Remberger K. Differential expression of 5 alpha-reductase isoenzymes in the human prostate and prostatic carcinomas. Prostate 29 (1996) 261-267
2. George F.W., Johnson L., and Wilson J.D. The effect of a 5 alpha-reductase inhibitor on androgen physiology in the immature male rat. Endocrinology 125 (1989) 2434-2438
3. Imperato-McGinley J., Gautier T., Zirinsky K., et al. Prostate visualization studies in males homozygous and heterozygous for 5 alpha-reductase deficiency. J Clin Endocrinol Metab 75 (1992) 1022-1026
4. Deslypere J.P., Young M., Wilson J.D., and McPhaul M.J. Testosterone and 5 alpha-dihydrotestosterone interact differently with the androgen receptor to enhance transcription of the MMTV-CAT reporter gene. Mol Cell Endocrinol 88 (1992) 15-22
5. Wright A.S., Douglas R.C., Thomas L.N., Lazier C.B., and Rittmaster R.S. Androgen-induced regrowth in the castrated rat ventral prostate: role of 5alpha-reductase. Endocrinology 140 (1999) 4509-4515
6. Andersson S., Berman D.M., Jenkins E.P., and Russell D.W. Deletion of steroid 5 alpha-reductase 2 gene in male pseudohermaphroditism. Nature 354 (1991) 159-161
7. Petrow V. The dihydrotestosterone (DHT) hypothesis of prostate cancer and its therapeutic implications. Prostate 9 (1986) 343-361
8. Farnsworth W.E., and Brown J.R. Androgen of the human prostate. Endocr Res Commun 3 (1976) 105-117
9. Isaacs J.T. Changes in dihydrotestosterone metabolism and the development of benign prostatic hyperplasia in the aging beagle. J Steroid Biochem 18 (1983) 749-757
10. Roehrborn C.G., Boyle P., Nickel J.C., Hoefner K., and Andriole G. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 60 (2002) 434-441
11. McConnell J.D., Bruskewitz R., Walsh P., et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med 338 (1998) 557-563
12. Xu Y., Dalrymple S.L., Becker R.E., Denmeade S.R., and Isaacs J.T. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers. Clin Cancer Res 12 (2006) 4072-4079
13. Thompson I.M., Goodman P.J., Tangen C.M., et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 349 (2003) 215-224
14. Canby-Hagino E., Hernandez J., Brand T.C., and Thompson I. Looking back at PCPT: looking forward to new paradigms on prostate cancer screening and prevention. Eur Urol 51 (2007) 27-33
15. Hamdy F.C. The prostate cancer prevention trial and its messages. Eur Urol 51 (2007) 6-8
16. Jenkins E.P., Andersson S., Imperato-McGinley J., Wilson J.D., and Russell D.W. Genetic and pharmacological evidence for more than one human steroid 5 alpha-reductase. J Clin Invest 89 (1992) 293-300
17. Jenkins E.P., Hsieh C.L., Milatovich A., et al. Characterization and chromosomal mapping of a human steroid 5 alpha-reductase gene and pseudogene and mapping of the mouse homologue. Genomics 11 (1991) 1102-1112
18. Normington K., and Russell D.W. Tissue distribution and kinetic characteristics of rat steroid 5 alpha-reductase isozymes. Evidence for distinct physiological functions. J Biol Chem 267 (1992) 19548-19554
19. Thigpen A.E., Silver R.I., Guileyardo J.M., et al. Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression. J Clin Invest 92 (1993) 903-910
20. Titus M., Li Y., Kawinski E., Kozyreva O., and Mohler J.L. Biochemical and pharmacological evidence for a third isozyme of steroid 5α-reductase in prostate cancer [abstract no. 268] (2007), American Urological Association, Anaheim (CA)
21. Silver R.I., Wiley E.L., Davis D.L., et al. Expression and regulation of steroid 5 alpha-reductase 2 in prostate disease. J Urol 152 (1994) 433-437
22. Carlin J.R., Höglund P., Eriksson L.O., et al. Disposition and pharmacokinetics of [14C] finasteride after oral administration in humans. Drug Metab Dispos 20 (1992) 148-155
23. Ohtawa M., Morikawa H., and Shimazaki J. Pharmacokinetics and biochemical efficacy after single and multiple oral administration of N-(2-methyl-2-propyl)-3-oxo-4-aza-5 alpha-androst-1-ene-17 beta-carboxamide, a new type of specific competitive inhibitor of testosterone 5 alpha-reductase, in volunteers. Eur J Drug Metab Pharmacokinet 16 (1991) 15-21
24. Tian G., Mook Jr. R.A., Moss M.L., and Frye S.V. Mechanism of time-dependent inhibition of 5 alpha-reductases by delta 1-4-azasteroids: towards perfection of rates of time-dependent inhibition by using ligand-binding energies. Biochemistry 34 (1995) 13453-13459
25. Evans H.C., and Goa K.L. Dutasteride. Drugs Aging 20 (2003) 906-916
26. Clark R.V., Hermann D.J., Cunningham G.R., et al. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor. J Clin Endocrinol Metab 89 (2004) 2179-2184
27. Wurzel R., Ray P., Major-Walker K., Shannon J., and Rittmaster R. The effect of dutasteride on intraprostatic dihydrotestosterone concentration in men with benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 10 (2007) 149-154
28. McConnell J.D., Wilson J.D., George F.W., et al. Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. J Clin Endocrinol Metab 74 (1992) 505-508
29. Span P.N., Voller M.C., Smals A.G., et al. Selectivity of finasteride as an in vivo inhibitor of 5alpha-reductase isozyme enzymatic activity in the human prostate. J Urol 161 (1999) 332-337
30. Andriole G.L., Humphrey P., Ray P., et al. Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor progression in prostate cancer. J Urol 172 (2004) 915-919
31. Iehle C., Radvanyi F., Gil Diez de Medina S., et al. Differences in steroid 5alpha-reductase iso-enzymes expression between normal and pathological human prostate tissue. J Steroid Biochem Mol Biol 68 (1999) 189-195
32. Thomas L.N., Lazier C.B., Gupta R., et al. Differential alterations in 5alpha-reductase type 1 and type 2 levels during development and progression of prostate cancer. Prostate 63 (2005) 231-239
33. Thomas L.N., Douglas R.C., Vessey J.P., et al. 5alpha-reductase type 1 immunostaining is enhanced in some prostate cancers compared with benign prostatic hyperplasia epithelium. J Urol 170 (2003) 2019-2025
34. Soderstrom T.G., Bjelfman C., Brekkan E., et al. Messenger ribonucleic acid levels of steroid 5 alpha-reductase 2 in human prostate predict the enzyme activity. J Clin Endocrinol Metab 86 (2001) 855-858
35. Luo J., Dunn T.A., Ewing C.M., Walsh P.C., and Isaacs W.B. Decreased gene expression of steroid 5 alpha-reductase 2 in human prostate cancer: implications for finasteride therapy of prostate carcinoma. Prostate 57 (2003) 134-139
36. Titus M.A., Gregory C.W., Ford III O.H., et al. Steroid 5alpha-reductase isozymes I and II in recurrent prostate cancer. Clin Cancer Res 11 (2005) 4365-4371
37. Bjelfman C., Soderstrom T.G., Brekkan E., et al. Differential gene expression of steroid 5 alpha-reductase 2 in core needle biopsies from malignant and benign prostatic tissue. J Clin Endocrinol Metab 82 (1997) 2210-2214
38. Andriole G., Bostwick D., Brawley O., et al. Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. J Urol 172 (2004) 1314-1317
39. Civantos F., Soloway M.S., and Pinto J.E. Histopathological effects of androgen deprivation in prostatic cancer. Semin Urol Oncol 14 (1996) 22-31
40. Cote R.J., Skinner E.C., Salem C.E., et al. The effect of finasteride on the prostate gland in men with elevated serum prostate-specific antigen levels. Br J Cancer 78 (1998) 413-418
41. Cussenot O., Azzouzi A.R., Nicolaiew N., et al. Low-activity V89L variant in SRD5A2 is associated with aggressive prostate cancer risk: an explanation for the adverse effects observed in chemoprevention trials using 5-alpha-reductase inhibitors. Eur Urol 52 (2007) 1082-1089
42. Akduman B., and Crawford E.D. The PCPT: new findings, new insights and clinical implications for the prevention of prostate cancer. Eur Urol Suppl 5 (2006) 634-639
43. Serfling R., Schulman M.T., Thompson G.L., et al. Quantifying the impact of prostate volumes, numbers of biopsy cores, and 5alpha-reductase inhibitor therapy on the probability of prostate cancer detection using mathematical modeling. J Urol 153 (2007) 2352-2356
44. Thomas L.N., Douglas R.C., Lazier C.B., et al. Levels of 5alpha-reductase type 1 and type 2 are increased in high grade compared to low grade prostate cancer [abstract no. 57] (2007), The American Society of Clinical Oncology, Orlando (FL)
45. Andriole G.L., Roehrborn C., Schulman C., et al. Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia. Urology 64 (2004) 537-541
46. Balk S.P. Androgen receptor as a target in androgen-independent prostate cancer. Urology 60 (2002) 132-138
47. Huggins C., and Hodges C.V. Studies on prostatic cancer: the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1 (1941) 293-297
48. Mike S, Harrison C, Coles B, et al. Chemotherapy for hormone-refractory prostate cancer. Cochrane Database Syst Rev 2006:CD005247.
49. Stanbrough M., Bubley G.J., Ross K., et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 66 (2006) 2815-2825
50. Zegarra-Moro O.L., Schmidt L.J., Huang H., and Tindall D.J. Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res 62 (2002) 1008-1013
51. Taplin M.E., Bubley G.J., Shuster T.D., et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 332 (1995) 1393-1398
52. Visakorpi T., Hyytinen E., Koivisto P., et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 9 (1995) 401-406
53. Taplin M.E., Bubley G.J., Ko Y.J., et al. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res 59 (1999) 2511-2515
54. Taplin M.E., Rajeshkumar B., Halabi S., et al. Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J Clin Oncol 21 (2003) 2673-2678
55. Culig Z. Role of the androgen receptor axis in prostate cancer. Urology 62 (2003) 21-26
56. Gregory C.W., He B., Johnson R.T., et al. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 61 (2001) 4315-4319
57. Weber M.J., and Gioeli D. Ras signaling in prostate cancer progression. J Cell Biochem 91 (2004) 13-25
58. Tay M.H., Kaufman D.S., Regan M.M., et al. Finasteride and bicalutamide as primary hormonal therapy in patients with advanced adenocarcinoma of the prostate. Ann Oncol 15 (2004) 974-978
59. Brufsky A., Fontaine-Roth P., Berlane K., et al. Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate. Urology 49 (1997) 913-920